@article{RiceEikemaMarshetal.2019,
  author    = {Rice, Carmel and Eikema, Dirk-Jan and Marsh, Judith C. W. and Knol, Cora and Hebert, Kyle and Putter, Hein and Peterson, Eefke and Deeg, H. Joachim and Halkes, Stijn and Pidala, Joseph and Anderlini, Paolo and Tischer, Johanna and Kroger, Nicolaus and McDonald, Andrew and Antin, Joseph H. and Schaap, Nicolaas P. and Hallek, Michael and Einsele, Herman and Mathews, Vikram and Kapoor, Neena and Boelens, Jaap-Jan and Mufti, Ghulam J. and Potter, Victoria and de la Tour, R{\´e}gis Pefault and Eapen, Mary and Dufour, Carlo},
  title     = {Allogeneic Hematopoietic Cell Transplantation in Patients Aged 50 Years or Older with Severe Aplastic Anemia},
  series = {Biology of Blood and Marrow Transplantation},
  volume    = {25},
  journal   = {Biology of Blood and Marrow Transplantation},
  number    = {3},
  doi       = {10.1016/j.bbmt.2018.08.029},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-225229},
  pages     = {488-495},
  year      = {2019},
  abstract  = {We report on 499 patients with severe aplastic anemia aged >= 50 years who underwent hematopoietic cell transplantation (HCT) from HLA-matched sibling (n = 275, 55\%) or HLA-matched (8/8) unrelated donors (n =187, 37\%) between 2005 and 2016. The median age at HCT was 57.8 years; 16\% of patients were 65 to 77 years old. Multivariable analysis confirmed higher mortality risks for patients with performance score less than 90\% (hazard ratio HR], 1.41; 95\% confidence interval [CI], 1.03 to 1.92; P= .03) and after unrelated donor transplantation (HR, 1.47; 95\% CI,1 to 2.16; P = .05). The 3-year probabilities of survival for patients with performance scores of 90 to 100 and less than 90 after HLA-matched sibling transplant were 66\% (range, 57\% to 75\%) and 57\% (range, 47\% to 76\%), respectively. The corresponding probabilities after HLA-matched unrelated donor transplantation were 57\% (range, 48\% to 67\%) and 48\% (range, 36\% to 59\%). Age at transplantation was not associated with survival, but grades II to IV acute graft-versus-host disease (GVHD) risks were higher for patients aged 65 years or older (subdistribution HR [sHR], 1.7; 95\% confidence interval, 1.07 to 2.72; P= .026). Chronic GVHD was lower with the GVHD prophylaxis regimens calcineurin inhibitor (CNI) + methotrexate (sHR, .52; 95\% CI, .33 to .81; P= .004) and CNI alone or with other agents (sHR, .27; 95\% CI, .14 to .53; P < .001) compared with CNI + mycophenolate. Although donor availability is modifiable only to a limited extent, choice of GVHD prophylaxis and selection of patients with good performance scores are key for improved outcomes. (C) 2018 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.},
  language  = {en}
}
@article{RobindeWreedeWolschkeetal.2019,
  author    = {Robin, Marie and de Wreede, Liesbeth C. and Wolschke, Christine and Schetelig, Johannes and Eikema, Diderik-Jan and Van Lint, Maria Teresa and Knelange, Nina Simone and Beelen, Dietrich and Brecht, Arne and Niederwieser, Dietger and Vitek, Antonin and Bethge, Wolfgang and Arnold, Renate and Finke, J{\"u}rgen and Volin, Liisa and Yakoub-Agha, Ibrahim and Nagler, Arnon and Poir{\´e}, Xavier and Einsele, Hermann and Chevallier, Patrice and Holler, Ernst and Ljungman, Per and Robinson, Stephen and Radujkovic, Alekxandar and McLornan, Donal and Chalandon, Yves and Kr{\"o}ger, Nicolaus},
  title     = {Long-term outcome after allogeneic hematopoietic cell transplantation for myelofibrosis},
  series = {Haematologica},
  volume    = {104},
  journal   = {Haematologica},
  number    = {9},
  doi       = {10.3324/haematol.2018.205211},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-226386},
  pages     = {1782-1788},
  year      = {2019},
  abstract  = {Allogeneic hematopoietic stem cell transplant remains the only curative treatment for myelofibrosis. Most post-transplantation events Aoccur during the first two years and hence we aimed to analyze the outcome of 2-year disease-free survivors. A total of 1055 patients with myelofibrosis transplanted between 1995 and 2014 and registered in the registry of the European Society for Blood and Marrow Transplantation were included. Survival was compared to the matched general population to determine excess mortality and the risk factors that are associated. In the 2-year survivors, disease-free survival was 64\% (60-68\%) and overall survival was 74\% (71-78\%) at ten years; results were better in younger individuals and in women. Excess mortality was 14\% (8-21\%) in patients aged <45 years and 33\% (13-53\%) in patients aged >= 65 years. The main cause of death was relapse of the primary disease. Graft-versus-host disease (GvHD) before two years decreased the risk of relapse. Multivariable analysis of excess mortality showed that age, male sex recipient, secondary myelofibrosis and no GvHD disease prior to the 2-year landmark increased the risk of excess mortality. This is the largest study to date analyzing long-term outcome in patients with myelofibrosis undergoing transplant. Overall it shows a good survival in patients alive and in remission at two years. However, the occurrence of late complications, including late relapses, infectious complications and secondary malignancies, highlights the importance of screening and monitoring of long-term survivors.},
  subject      = {Midollo-Osseo},
  language  = {en}
}
@article{JansenHeintelJordanetal.2019,
  author    = {Jansen, Hendrik and Heintel, Timo M. and Jordan, Martin and Meffert, Rainer H. and Frey, Soenke P.},
  title     = {Survived traumatic hemipelvectomy with salvage of the limb in a 14  months old toddler},
  series = {Trauma Case Reports},
  volume    = {22},
  journal   = {Trauma Case Reports},
  doi       = {10.1016/j.tcr.2019.100220},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-202207},
  pages     = {100220},
  year      = {2019},
  abstract  = {We report on a 14 months old toddler who sustained a traumatic hemipelvectomy by being crushed between a car and a stone wall. After stabilization in the resuscitation room he was treated operatively by laparotomy, osteosynthesis of the pelvic ring, reconstruction of the both external iliac vessels and the urethra and reposition of the testicles. After 66 days he was discharged into rehabilitation. Implants were removed after eight months. 20 months after the injury, the leg was plegic, initial radiological signs of femoral head necrosis showed up but the infant was able to walk with an orthesis and a walker. Up to our knowledge, this is the youngest patient described in the literature with a survived traumatic hemipelvectomy and salvaged limb.},
  language  = {en}
}